AU616386B2 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions

Info

Publication number
AU616386B2
AU616386B2 AU81914/87A AU8191487A AU616386B2 AU 616386 B2 AU616386 B2 AU 616386B2 AU 81914/87 A AU81914/87 A AU 81914/87A AU 8191487 A AU8191487 A AU 8191487A AU 616386 B2 AU616386 B2 AU 616386B2
Authority
AU
Australia
Prior art keywords
sub
sup
alkyl
cycloalkyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU81914/87A
Other versions
AU8191487A (en
Inventor
Michael Brian Tyers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU616386(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AU8191487A publication Critical patent/AU8191487A/en
Application granted granted Critical
Publication of AU616386B2 publication Critical patent/AU616386B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Abstract

The invention relates to the use of compounds of the general formula (I)whereinR' represents a hydrogen atom or a C<sub>1-10</sub> alkyl, C<sub>3-7</sub> cycloalkyl, C<sub>3-7</sub> cycloalkyl-(C<sub>1-4</sub>) alkyl, C<sub>3</sub>-<sub>6</sub> alkenyl, C<sub>3-10</sub> alkynyl, phenyl or phenyl-C<sub>1-3</sub> alkyl group; and one of the groups represented byR<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> is a hydrogen atom or a C<sub>1-3</sub> alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub> alkenyl or phenyl - C<sub>1-3</sub> alkyl group and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C<sub>1-6</sub> alkyl group; and physiologically acceptable salts and solvates thereof, for the relief of nausea and vomiting and/or the promotion of gastric emptying and for the manufacture of a medicament for this purpose. Promotion of gastric emptying may be for the relief of gastro-intestinal disorders associated with gastric stasis or may be of advantage in radiological examination procedures.The invention also relates to a product containing a therapeutic agent liable to induce nausea and vomiting, e.g. a cytostatic agent such as a cyclophosphamide, an alkylating agent or a platinum complex, and a compound of the general formula (1) as a combined preparation for simultaneous separate or sequential use in therapy.
AU81914/87A 1985-06-25 1987-11-30 Pharmaceutical compositions Ceased AU616386B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB8628474 1986-11-28
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
AU8191487A AU8191487A (en) 1988-06-02
AU616386B2 true AU616386B2 (en) 1991-10-31

Family

ID=40347948

Family Applications (2)

Application Number Title Priority Date Filing Date
AU67037/86A Expired AU609028B2 (en) 1985-06-25 1986-12-30 New medical use of tetrahydrocarbazolones derivative
AU81914/87A Ceased AU616386B2 (en) 1985-06-25 1987-11-30 Pharmaceutical compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU67037/86A Expired AU609028B2 (en) 1985-06-25 1986-12-30 New medical use of tetrahydrocarbazolones derivative

Country Status (22)

Country Link
US (2) US4753789A (en)
EP (2) EP0431443A3 (en)
JP (2) JPS6253920A (en)
AT (2) ATE134510T1 (en)
AU (2) AU609028B2 (en)
BE (1) BE1002249A4 (en)
CA (1) CA1296637C (en)
CH (1) CH672068A5 (en)
CY (1) CY2000A (en)
DE (2) DE3650488T2 (en)
DK (1) DK624687A (en)
FR (1) FR2613934B1 (en)
GB (3) GB8516083D0 (en)
HK (1) HK82597A (en)
IE (1) IE60908B1 (en)
IL (1) IL84638A (en)
IT (1) IT1211937B (en)
NL (1) NL8702853A (en)
NZ (1) NZ222743A (en)
SE (1) SE8704747L (en)
SG (1) SG43311A1 (en)
ZA (1) ZA878927B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3688296T2 (en) * 1985-03-14 1993-11-04 Beecham Group Plc MEDICINES FOR TREATING EMERGENCY.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
JP2608078B2 (en) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド Medicine
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
JPH0754759B2 (en) * 1987-04-27 1995-06-07 日本電信電話株式会社 Plasma processing method and apparatus, and mode converter for plasma processing apparatus
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (en) * 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
AU2295792A (en) * 1991-06-26 1993-01-25 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
CA2112488A1 (en) * 1991-06-26 1993-01-07 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
DK0533280T4 (en) * 1991-09-20 2005-02-28 Glaxo Group Ltd New medical use of tachykinin antagonists
KR960700711A (en) * 1993-03-08 1996-02-24 후지야마 아키라 Medicine for treating or preventing cerebrovascular diseases
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
US6548082B1 (en) * 1999-03-01 2003-04-15 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron
KR100434390B1 (en) * 2001-04-20 2004-06-04 안국약품 주식회사 The composition for nasal solution sprays having effective component of 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-y1)methyl]-4H-carbazol-4-one
JP5690461B2 (en) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム Palonosetron for treating chemotherapy-induced vomiting
JP2006516977A (en) * 2003-01-13 2006-07-13 ダイノゲン ファーマシューティカルズ,インコーポレイテッド How to treat nausea, vomiting, retching, or any combination thereof
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
WO2005108392A2 (en) * 2004-05-07 2005-11-17 Taro Pharmaceutical Industries Ltd. Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
ME01949B (en) * 2006-10-24 2010-08-31 Soft capsules comprising palonosetron hydrochloride having improved stability and bioavailability
JP2010050046A (en) 2008-08-25 2010-03-04 Hitachi High-Technologies Corp Plasma treatment device
CA2784587A1 (en) 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
MX342993B (en) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Process to obtain random copolymers derived from itaconic acid and/or its isomers and sodium alkenyl sulfonates and use of the product thereof.
EP3589369A4 (en) * 2017-01-09 2020-03-18 DAS-MG, Inc. Use and composition for treating myasthenia gravis and other myasthenic syndromes

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (en) * 1980-05-17 1981-11-25 FISONS plc Mixtures, salts, packages and pharmaceutical compositions containing 5-(2-hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carboxylic acid or a derivative thereof and an H2 receptor antagonist antihistamine
BE894285A (en) * 1981-09-04 1983-03-02 Glaxo Group Ltd PHARMACEUTICAL COMPOSITION CONTAINING AN ANTI-INFLAMMATORY MEDICINAL PRODUCT AND RANITIDINE OR A SALT THEREOF
FR2557110B1 (en) * 1983-12-23 1989-11-24 Sandoz Sa NOVEL CYCLIC AMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
FI84349C (en) * 1984-01-25 1991-11-25 Glaxo Group Ltd PROCEDURE FOR THE FRAMEWORK OF PHARMACOLOGICAL PROPERTIES.
DE3680123D1 (en) * 1985-01-23 1991-08-14 Glaxo Group Ltd Tetrahydrocarbazolonderivate.
DE3688296T2 (en) * 1985-03-14 1993-11-04 Beecham Group Plc MEDICINES FOR TREATING EMERGENCY.
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
GB8628474D0 (en) 1987-01-07
AT395374B (en) 1992-12-10
AU6703786A (en) 1988-06-30
IE873230L (en) 1988-05-28
EP0431443A3 (en) 1991-09-18
SE8704747D0 (en) 1987-11-27
SG43311A1 (en) 1997-10-17
DK624687A (en) 1988-05-29
DK624687D0 (en) 1987-11-27
IT1211937B (en) 1989-11-08
ZA878927B (en) 1988-10-26
EP0226266A3 (en) 1990-01-24
JPS6253920A (en) 1987-03-09
JPS63198623A (en) 1988-08-17
DE3740351A1 (en) 1988-06-09
GB2200046A (en) 1988-07-27
SE8704747L (en) 1988-05-29
IE60908B1 (en) 1994-08-24
IL84638A (en) 1992-05-25
DE3650488T2 (en) 1996-09-05
CY2000A (en) 1997-12-05
AU609028B2 (en) 1991-04-26
ATE134510T1 (en) 1996-03-15
GB2200046B (en) 1990-09-26
AU8191487A (en) 1988-06-02
GB8516083D0 (en) 1985-07-31
FR2613934A1 (en) 1988-10-21
US4929632A (en) 1990-05-29
HK82597A (en) 1997-06-27
CH672068A5 (en) 1989-10-31
DE3650488D1 (en) 1996-04-04
EP0226266B1 (en) 1996-02-28
EP0431443A2 (en) 1991-06-12
FR2613934B1 (en) 1993-07-09
BE1002249A4 (en) 1990-11-06
IT8748643A0 (en) 1987-11-27
NL8702853A (en) 1988-06-16
EP0226266A2 (en) 1987-06-24
CA1296637C (en) 1992-03-03
ATA312587A (en) 1992-05-15
JPH0324447B2 (en) 1991-04-03
GB8727836D0 (en) 1987-12-31
NZ222743A (en) 1991-09-25
US4753789A (en) 1988-06-28

Similar Documents

Publication Publication Date Title
AU616386B2 (en) Pharmaceutical compositions
ES530242A0 (en) A PROCEDURE FOR PREPARING SALTS FROM AN IMIDAZOLE DERIVATIVE
ES8506615A1 (en) N-aryl-alpha-amino-carboxamides.
IL92358A0 (en) Diaryl compounds,their preparation and pharmaceutical compositions containing them
AU8240387A (en) Basically substituted phenylacetonitriles, their preparation and drugs containing these compounds
IL70253A (en) N-nitrosourea phosphoric acid derivatives,their preparation and pharmaceutical compositions containing them
AU2585188A (en) New N-(23-vinblastinoyl) derivatives of 1-aminomethyl- phosphonic acid, processes for preparing them and pharmaceutical compositions containing them
CA2211982A1 (en) Substituted indanylidineacetylguanidines, process for their preparation,their use as medicaments or diagnostic and medicaments containing them
ES2001893A6 (en) Methylendioxyphenathrene and stilben derivatives, process for the preparation thereof, pharmaceutical compositions using these, and therapeutic applications
ES8504112A1 (en) Microbicidal benzamidine derivatives, their preparation and their use in pharmaceutical compositions as disinfection or preservation agents.
ATE91890T1 (en) MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM.
EP0204172A3 (en) Phenylpyrazine derivatives, processes for preparing them, pharmaceutical composition and use
EP0202950A3 (en) Berban derivatives and their preparation and pharmaceutical formulation
ES8504816A1 (en) Cephalosporin antibiotics.
ES487971A1 (en) P-Chloroacetophenone oxime compounds and pharmaceutical compositions
ES8201152A1 (en) 5-Sulfamoyl-orthanilic acids, processes for their preparation, therapeutic compositions containing them and the compounds for use in therapy.
EP0133578A3 (en) 3-aryl-3-pyrroline derivatives, process for their preparation, and medicaments containing them for the treatment of heart and vascular diseases

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired